ClinicalTrials.gg
CompletedNCT01730404Updated Mar 29, 2017

Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients

A Phase 2 interventional study of CHF6001 DPI and Roflumilast in COPD, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 5 sites in 2 countries. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. tanimilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
5th of 12
55 · median 46
Started
2012
the only one that year
Phase 2
3 of 12
none open now
Registered
1st of 12
by date
Lead sponsor
12 of 12
Chiesi Farmaceutici S.p.A.

Among the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive, this one is the 5th largest by enrollment, is the only one that started in 2012, is one of 3 in phase 2, and was the 1st registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About tanimilast

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing tanimilast in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

Phase IIa study in COPD patients aimed to evaluate the safety, tolerability ,pharmacodynamics (effect on biological markers of inflammation in induced sputum and in blood, and on pulmonary function) and on pharmacokinetics of CHF 6001 (a PDE4 inhibitor) after 28-days of daily inhaled dosing.

03

Conditions studied

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained prior to any study-related procedures.
  2. Male or female aged between 40 and 70 years inclusive.
  3. Current or past smoker of at least 10 pack/years
  4. in the range of 18-35 Kg/m2
  5. GOLD Stage 2 and 3 subjects
  6. A history of chronic bronchitis defined as chronic cough and sputum production
  7. At screening, subjects must be able to produce an adequate induced sputum sample
  8. Female subjects: women having at least 12 months of natural (spontaneous) amenorrhea, or women of using two acceptable methods of for the duration of the study and for the following three months

Exclusion criteria

Exclusion criteria:

  1. Female subjects: pregnant or lactating women
  2. Past or current history of asthma
  3. History of hypotensive episodes
  4. History or symptoms of significant cardiovascular disease
  5. History or symptoms of significant neurological disease
  6. Unstable concurrent disease
  7. An abnormal and clinically significant 12-lead
  8. Clinically relevant abnormal laboratory values
  9. Use of oral or systemic oral and/or nebulised Beta2 agonists and/or antibiotics within 6 weeks preceding the screening visit
  10. Moderate or severe hepatic impairment ( B or C)
  11. Intolerance/ or any to treatment with roflumilast, tiotropium bromide or salbutamol or any of the contained in the formulations used in the study
  12. Chronic use of any other medication for treatment of lung disease like xanthines, antileukotrienes, systemic and inhaled corticosteroids, long acting beta2- agonists, roflumilast (other than the study drug) and cromoglycates
  13. Long term (at least 12 hours daily) use of oxygen therapy for chronic hypoxemia.
  14. Having received an medicinal drug within 30 days prior to study entry
  15. Blood draws of 250 mL or more within 45 days prior to enrolment into the study.
  16. Known respiratory disorders other than .
  17. History of alcohol dependency, or substance abuse
  18. Inability to comply with the study Protocol for any other reason.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    CHF6001

    CHF6001 DPI (Dry Powder Inhaler) once daily

    Drug: CHF6001 DPI

  • Active comparator
    Roflumilast

    Roflumilast, tablet, once daily

    Drug: Roflumilast

  • Placebo comparator
    placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events, adverse drug reactions, serious adverse.

    The number and percentage of subjects experiencing AEs, ADRs, serious AEs and AEs leading to study withdrawal.

    Time frame: After 28 days of treatment

  2. Vital signs

    Time frame: After 28 days of treatment

  3. 12-lead ECG parameters

    Time frame: After 28 days of treatment

Secondary outcomes

  1. Pharmacokinetics of CHF 6001 and its metabolites

    Time frame: After 28 days of treatment

  2. Induction of sputum

    Biomarkers of inflammation

    Time frame: After 28 days of treatment

  3. Baseline Dyspnea Index and Transition Dyspnea Index Questionnaire

    Time frame: After 28 days of treatment

  4. Lung function measurements

    Time frame: After 28 days of treatment

07

Study locations

5 sites
  • Celerion
    Belfast, Ireland
  • Parexel, early phases
    Harrow, United Kingdom
  • Medicines Evaluation Unit Ltd
    Manchester, United Kingdom
  • Freeman Hospital
    Newcastle, United Kingdom
  • Nottingham University Hospitals NHS Trust
    Nottingham, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2012
First posted
Nov 21, 2012
Start
Oct 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Last update
Mar 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01730404
Responsible party
Sponsor
First posted
Nov 21, 2012
Start date
Oct 2012
Primary completion
Oct 2013
Completion
Oct 2013
Last update
Mar 29, 2017

Study contacts

Dave Singh, MD
principal investigator · Medicines Evaluation Unit Ltd
Anthony DeSoyza, MD
principal investigator · Freeman Health System
Stephen Smith, MD
principal investigator · Celerion
Tim Harrison, MD
principal investigator · Nottingham University Hospitals NHS Trust
Muna Albayaty, MD
principal investigator · Parexel, early phases

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tanimilast

Start the discussion